CPI-203

CPI-203
Item number Size Datasheet Manual SDS Delivery time Quantity Price
LKT-C6132.1 1 mg -

3 - 8 business days*

119.00€
LKT-C6132.5 5 mg -

3 - 8 business days*

389.00€
LKT-C6132.25 25 mg -

3 - 8 business days*

841.00€
 
CPI-203 is an orally available derivative of triazolothienodiazepine JQ-1, it exhibits no... more
Product information "CPI-203"
CPI-203 is an orally available derivative of triazolothienodiazepine JQ-1, it exhibits no sedative or anxiolytic efficacy and is currently in development as a potential anticancer compound. Like JQ-1, CPI-203 inhibits the BET bromodomain (BRD) family of proteins, including BRD4, inhibition of this protein downregulates Myc expression and IL-6 production in vitro. This compound also inhibits phosphorylation of the carboxyl-terminus domain of RNA polymerase II.
Supplier: LKT Laboratories
Supplier-Nr: C6132

Properties

Application: BRD4 inhibitor
MW: 399.9 D
Purity: >99%
Format: Solid

Database Information

KEGG ID : K11722 | Matching products

Handling & Safety

Storage: +20°C
Shipping: +20°C (International: +20°C)
Caution
Our products are for laboratory research use only: Not for administration to humans!
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "CPI-203"
Write a review
or to review a product.
Viewed